{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:55:01Z","timestamp":1790146501333,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,4,5]],"date-time":"2007-04-05T00:00:00Z","timestamp":1175731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,4,5]],"date-time":"2007-04-05T00:00:00Z","timestamp":1175731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s00262-007-0310-7","type":"journal-article","created":{"date-parts":[[2007,4,4]],"date-time":"2007-04-04T11:27:42Z","timestamp":1175686062000},"page":"1637-1644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM\u00a0\u00d7\u00a0anti-CD3): a phase I study"],"prefix":"10.1007","volume":"56","author":[{"given":"Martin","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernward","family":"Passlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Friccius-Quecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Lindhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kanniess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Wiewrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,4,5]]},"reference":[{"key":"310_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2004.11.048","volume":"225","author":"M Munz","year":"2005","unstructured":"Munz M, Zeidler R, Gires O (2005) The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 225:151\u2013157","journal-title":"Cancer Lett"},{"key":"310_CR2","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1073\/pnas.76.3.1438","volume":"76","author":"M Herlyn","year":"1979","unstructured":"Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76:1438\u20131442","journal-title":"Proc Natl Acad Sci USA"},{"key":"310_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-065X.1995.tb00078.x","volume":"145","author":"GJ Fleuren","year":"1995","unstructured":"Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S, Warnaar SO (1995) Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 145:91\u2013122","journal-title":"Immunol Rev"},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PT Went","year":"2004","unstructured":"Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122\u2013128","journal-title":"Hum Pathol"},{"key":"310_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","volume":"94","author":"P Went","year":"2006","unstructured":"Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Krononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128\u2013135","journal-title":"Br J Cancer"},{"key":"310_CR6","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1038\/sj.onc.1207610","volume":"23","author":"M Munz","year":"2004","unstructured":"Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748\u20135758","journal-title":"Oncogene"},{"key":"310_CR7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/002215540104900711","volume":"49","author":"R Riesenberg","year":"2001","unstructured":"Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM\u00a0\u00d7\u00a0alpha CD3). J Histochem Cytochem 49:911\u2013917","journal-title":"J Histochem Cytochem"},{"key":"310_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261\u2013266","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"310_CR9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/jco.2004.22.90140.2504","volume":"23","author":"M Jaeger","year":"2004","unstructured":"Jaeger M, Stroehlein MA, Schoberth A, Burges A, Heiss MM, Lindhofer H (2004) Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I\/II study. J Clin Oncol 23(Suppl):2504","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"310_CR10","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/jco.2004.22.90140.2532","volume":"23","author":"M Stroehlein","year":"2004","unstructured":"Stroehlein M, Jaeger M, Lindhofer H, Peschel C, Jauch KW, Heiss MM (2004) Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. J Clin Oncol 23(Suppl):2532","journal-title":"J Clin Oncol"},{"key":"310_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cncr.20288","volume":"101","author":"A Jemal","year":"2004","unstructured":"Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jaminson PM, Wingo PA, Howe HL, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975\u20132001, with a special feature regarding survival. Cancer 101:3\u201327","journal-title":"Cancer"},{"key":"310_CR12","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1056\/NEJMoa043623","volume":"352","author":"T Winton","year":"2005","unstructured":"Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589\u20132597","journal-title":"N Engl J Med"},{"key":"310_CR13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","volume":"350","author":"The International Adjuvant Lung Cancer Trial Collaborative Group","year":"2004","unstructured":"The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351\u2013360","journal-title":"N Engl J Med"},{"key":"310_CR14","doi-asserted-by":"crossref","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DF, ECOG (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398","DOI":"10.1056\/NEJMoa011954"},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"310_CR16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/jco.2005.23.16_suppl.lba4","volume":"23","author":"AB Sandler","year":"2005","unstructured":"Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II\/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23:24","journal-title":"J Clin Oncol"},{"key":"310_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJM200201103460211","volume":"346","author":"DN Carney","year":"2002","unstructured":"Carney DN (2002) Lung cancer\u2014time to move on from chemotherapy. N Engl J Med 346:126\u2013128","journal-title":"N Engl J Med"},{"key":"310_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000130554","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"310_CR19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","volume":"163","author":"R Zeidler","year":"1999","unstructured":"Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246\u20131252","journal-title":"J Immunol"},{"key":"310_CR20","first-page":"3499","volume":"21","author":"R Zeidler","year":"2001","unstructured":"Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A (2001) TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499\u20133503","journal-title":"Anticancer Res"},{"key":"310_CR21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","volume":"98","author":"P Ruf","year":"2001","unstructured":"Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526\u20132534","journal-title":"Blood"},{"key":"310_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<62::AID-IJC12>3.0.CO;2-T","volume":"84","author":"S Miotti","year":"1999","unstructured":"Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JM, Colnaghi MI, Canevari S (1999) Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC\/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84:62\u201368","journal-title":"Int J Cancer"},{"key":"310_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00262-006-0148-4","volume":"55","author":"I Azinovic","year":"2006","unstructured":"Azinovic I, Denardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55:1451\u20131458","journal-title":"Cancer Immunol Immunother"},{"key":"310_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1054\/bjoc.1999.0945","volume":"82","author":"G Molema","year":"2000","unstructured":"Molema G, Tervaer JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF (2000) CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro. Br J Cancer 82:472\u2013479","journal-title":"Br J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-007-0310-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0310-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:25:40Z","timestamp":1683797140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-007-0310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,5]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s00262-007-0310-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,5]]},"assertion":[{"value":"27 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}